Google
DNTH — DIANTHUS THERAPEUTICS INC. (Healthcare >> Biotechnology)
DNTH FAQ
What is DNTH's P/E ratio?
DIANTHUS THERAPEUTICS INC. (DNTH) currently trades at a P/E ratio of 47.44.
What is DNTH's ROE?
DIANTHUS THERAPEUTICS INC. reports a Return on Equity (ROE) of -0.94%.
What is DNTH's dividend yield?
DIANTHUS THERAPEUTICS INC. offers a dividend yield of 0.00%.
What is DNTH's Deepscope Quality Score?
Deepscope rates DNTH's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy DNTH?
Deepscope's AI Timing Score for DNTH is 71 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does DNTH belong to?
DIANTHUS THERAPEUTICS INC. is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 80.51
Price
-3.62
(-4.30%)
Day Change
|
|
|---|
DNTH, the overall quality is not good ( Quality = 23) but the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
P/E ratio is relatively high
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...
| Quality Factors |
|
39% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 90 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 80.51 |
| PBV / Sector |
3.87 / 4.63
|
| Earning Per Share | -0.20 |
| PE / Sector |
47.44 / 17.43
|
| PEG or PE/Growth / Sector |
14.51 / 0.53
|
| Average 1M Daily Value |
49.83 M
GREAT
|
| Average 1W Daily Value |
65.08 M
|
| Timing Factors |
|
14% |
| Financial Health |
|
37% |
| Ability to Make Profit |
|
60% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-06 09:09:23 |
| Symbol | DNTH |
| Name | DIANTHUS THERAPEUTICS INC. |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 54.67 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 4,644.99 / 8,857.28 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 7 Times Square, New York, NY, United States, 10036
Phone: 929 999 4055
Website: https://dianthustx.com
Employees: 92
Sector: Healthcare >> Biotechnology
Description: Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
